Oxford, UK based Pathios Therapeutics is targeting GPR65 for cancer, a signaling pathway that becomes active in the low pH tumor microenvironment and causes immunosuppression and high angiogenesis

BiotechTV - News - Oxford, UK based Pathios Therapeutics is targeting GPR65 for cancer, a signaling pathway that becomes active in the low pH tumor microenvironment and causes immunosuppression and high angiogenesis